{"id":744585,"date":"2023-04-03T08:30:41","date_gmt":"2023-04-03T12:30:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/"},"modified":"2023-04-03T08:30:41","modified_gmt":"2023-04-03T12:30:41","slug":"procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/","title":{"rendered":"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., April  03, 2023  (GLOBE NEWSWIRE) &#8212; PROCEPT<sup>\u00ae<\/sup>\u00a0BioRobotics Corporation (Nasdaq: PRCT) (the \u201cCompany\u201d), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that United Healthcare published an update to its Prostate Surgeries and Interventions Policy Bulletin that states Aquablation<sup>\u00ae<\/sup> therapy is proven and medically necessary for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) when performed according to the FDA labeled indications, contraindications, warnings and precautions. The updated policy follows Aquablation\u2019s FDA label and is effective June 1, 2023.<\/p>\n<p>United Healthcare is the largest health insurance company in the United States with over 45 million covered lives.<\/p>\n<p>\u201cWe are very excited to announce the updated policy from United Healthcare and believe this will greatly improve accessibility of Aquablation therapy for men suffering from BPH.\u201d said Reza Zadno, President and CEO. \u201cWith the addition of United Healthcare, we estimate approximately 95% of all men in the United States now have access to Aquablation therapy.\u201d<\/p>\n<p>United Healthcare\u2019s updated BPH coverage policy can be found here:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:5pt\">\n          <a href=\"https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/index\/commercial\/prostate-surgery-06012023.pdf\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/index\/commercial\/prostate-surgery-06012023.pdf<\/a><br \/>\n          \n        <\/li>\n<\/ul>\n<p>\n        <strong>About Aquablation Therapy<\/strong><br \/>\n        <br \/>Aquablation therapy is the first and only image-guided, automated robotic therapy with heat-free resection, for the treatment of BPH. The system\u2019s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient\u2019s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped, the automated robot removes prostate tissue in a precise, targeted, and controlled fashion using novel, heat-free waterjet technology.<\/p>\n<p>This novel technology is backed by numerous peer-reviewed publications demonstrating its safety, efficacy, and the durability of its outcomes. The cornerstone of the data is two prospective FDA trials with 5-year data; WATER and WATER II. The WATER study (the U.S. pivotal trial for FDA approval) randomized Aquablation against TURP, which has been the standard of care for resection of prostates smaller than 80ml, in a double-blinded study. The trial demonstrated superior safety and comparable efficacy to TURP in prostates 30ml to 80ml in size and superior safety and efficacy in prostates 50ml to 80ml in size. The WATER II study included men with a prostate size greater than 80ml undergoing Aquablation. The study met its pre-specified performance goal for safety and efficacy. The two FDA trials with 5-year follow-up have demonstrated consistent results across various prostate anatomy.<\/p>\n<p>\n        <strong>About PROCEPT BioRobotics Corporation<\/strong><br \/>\n        <br \/>PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This release contains forward\u2010looking statements within the meaning of federal securities laws, including with respect to the Company\u2019s projected financial performance for full year 2022, statements regarding the potential utilities, values, benefits and advantages of Aquablation<sup>\u00ae<\/sup> therapy performed using PROCEPT BioRobotics\u2019 products, including AquaBeam<sup>\u00ae<\/sup> Robotic System, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, the Company\u2019s possible or assumed future results of operations, including descriptions of the Company\u2019s revenues, gross margin, profitability, operating expenses, installed base growth, commercial momentum, overall business or the overall macroeconomic environment, which may impact customer spending or the Company\u2019s costs. Forward\u2010looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward\u2010looking statements are based on the Company\u2019s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward\u2010looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including the Company\u2019s annual report on Form 10-K filed with the SEC on February 28, 2023. PROCEPT BioRobotics does not undertake any obligation to update forward\u2010looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward\u2010looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics\u2019 views as of any date subsequent to the date of this press release.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vx_zh74doPDz7igBymytUl4vJJyKtJEgkIjwOQYLHinMYA3bTEJsfPJhQIe1Q9EweVLn413BWK5ghSe769_8q3HzB12x1gFi7vq4CNF5rLOUxlz2l3GGW96TbGxdMBTzzWoqNWp0xIYE12qCr2Aip8Apmtrs4TeFMTGqXFjFxC5hKWkr6zmXKJyp761KBvvy96yRDoHFqnANGxn6xpbDyujDcp5xn9XI8EwivKKbmfylQiL-DG-BnfGFlDYQpGvwamaNnVnOIjJmiwY4T6qkcNY6uDPog7XY1JjuJn9s-zI=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>Important Safety Information<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>All surgical treatments have inherent and associated side effects. For a list of potential side effects visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wDtIMSD1L-_88AnuFLRPdznKGaEvADwOcjB8zZNdv0bUsl7WsOkXzmb4bDTpKVaw0sdWQ3iTI8-Fbf9NkitBeorhnH6RgbMer5mdft_PzYgEx78rgmd9_kVyqY0TddmAW-pNBsKxd67RpPW4QcEX7gOXZ-9NIk_6uxrrPdtJjL8t7jMArHlbxFx533JwzoCpZrqb8jgajofpW27yB_MbMWxowhI5Zwbw-FxwY6uvSw7N71iKl0ZJAqizTxBJU7zmBdKz4Hyr6f3yOSIkOdWQx-6Kj_N93N9HDRhb7vNKZpHayXH4Ygc_omaaBeg_4PSjAK5QupONjXtePkNIpgTxu0luYm_AoH9Nh8GrFVgMjq0=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/aquablation.com\/safety-information\/<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Matt Bacso, CFA<br \/>VP, Investor Relations and Business Operations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2pUikcq4LwFSJyGlveRMgrL315AzOibFiiDgUJ0YoQNVztbAU413o4-SW7nq9PTJX5Szr3QHce4usuMBwaYl3b3Wq0l-HBAkmyogSBc_H2cVaCb3ITskzR99EZbK3jZT\" rel=\"nofollow noopener\" target=\"_blank\">m.bacso@procept-biorobotics.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTQ3NmU2ZjAtZDhhMi00ZGVlLWIzNDAtMTdmOTc2NGU3MTIxLTExOTA2Nzk=\/tiny\/PROCEPT-BioRobotics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) &#8212; PROCEPT\u00ae\u00a0BioRobotics Corporation (Nasdaq: PRCT) (the \u201cCompany\u201d), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that United Healthcare published an update to its Prostate Surgeries and Interventions Policy Bulletin that states Aquablation\u00ae therapy is proven and medically necessary for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) when performed according to the FDA labeled indications, contraindications, warnings and precautions. The updated policy follows Aquablation\u2019s FDA label and is effective June 1, 2023. United Healthcare is the largest health insurance company in the United States with over 45 million covered lives. \u201cWe are very excited to announce the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-744585","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) &#8212; PROCEPT\u00ae\u00a0BioRobotics Corporation (Nasdaq: PRCT) (the \u201cCompany\u201d), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that United Healthcare published an update to its Prostate Surgeries and Interventions Policy Bulletin that states Aquablation\u00ae therapy is proven and medically necessary for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) when performed according to the FDA labeled indications, contraindications, warnings and precautions. The updated policy follows Aquablation\u2019s FDA label and is effective June 1, 2023. United Healthcare is the largest health insurance company in the United States with over 45 million covered lives. \u201cWe are very excited to announce the &hellip; Continue reading &quot;PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-03T12:30:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates\",\"datePublished\":\"2023-04-03T12:30:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/\"},\"wordCount\":976,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/\",\"name\":\"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=\",\"datePublished\":\"2023-04-03T12:30:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/","og_locale":"en_US","og_type":"article","og_title":"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates - Market Newsdesk","og_description":"REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) &#8212; PROCEPT\u00ae\u00a0BioRobotics Corporation (Nasdaq: PRCT) (the \u201cCompany\u201d), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that United Healthcare published an update to its Prostate Surgeries and Interventions Policy Bulletin that states Aquablation\u00ae therapy is proven and medically necessary for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) when performed according to the FDA labeled indications, contraindications, warnings and precautions. The updated policy follows Aquablation\u2019s FDA label and is effective June 1, 2023. United Healthcare is the largest health insurance company in the United States with over 45 million covered lives. \u201cWe are very excited to announce the &hellip; Continue reading \"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-03T12:30:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates","datePublished":"2023-04-03T12:30:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/"},"wordCount":976,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/","name":"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=","datePublished":"2023-04-03T12:30:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMDI2MyM1NTA1MjUwIzIxNzkxMTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/procept-biorobotics-corp-announces-united-healthcare-coverage-of-aquablation-therapy-for-men-with-enlarged-prostates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=744585"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744585\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=744585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=744585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=744585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}